About Qlife Holding
Qlife is a high-tech medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it the most. Its main product, The Egoo Home System, is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient’s doctor, clinic or hospital via smartphone and computer. Qlife is headquartered in Helsingborg, Sweden.
Missing: Qlife Holding's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Qlife Holding's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Qlife Holding
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Qlife Holding is included in 4 Expert Collections, including Health Monitoring & Diagnostics.
Health Monitoring & Diagnostics
At-home IVD test developers, at-home sample collection device developers, at-home testing service providers, and all other companies playing in the at-home testing ecosystem. Companies tagged as #AtHomeTestingEcosystem
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Latest Qlife Holding News
Nov 30, 2022
HC Andersen Capital Wed, Nov 30, 2022 08:20 CET QLIFE HOLDING – PRESENTATION OF Q3 INTERIM REPORT 2022 Qlife Holding has recently published their interim report for Q3 2022. Revenue in the period amounted to kSEK 1,967 (5,871). Revenue includes sales of Egoo.Health devices and capsules for the device. The company has continued decline in test activity following the end of Covid travel restrictions has led to a decline in revenue in line with expectations from the company. EBITDA for the period amounted to kSEK -14,850 (-12,146), and net loss kSEK -20,678 (-12,268). Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarker and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases. Qlife Holding was formed in October 2019 and received the certification ISO 13485:2016 the same year, which means that Qlife meets all requirements for the manufacture and sale of in-vitro diagnostic analyzers and reagents. The first capsules in the company's product, Egoo.Health Platform, was CE marked for professional use in early 2020. The company has patent protection for key parts of its technology. Meet Qlife Holding’s CEO Thomas Warthoe and CFO Kasper Rousøe when they present the Q3 report. Wednesday November 30, 13:00-13:30 ------------------------------------------- Disclaimer: HC Andersen Capital receives payment from the companies mentioned for a DigitalIR/Corporate Visibility agreement. The content is not buy or sell recommendations. Mie Halse firstname.lastname@example.org +45 28746640 #DigitalIR is the digitalization of the relationship between investors and stock-listed companies. #DemocraticIR is the basic idea that all investors should have access to equal information.
Qlife Holding Frequently Asked Questions (FAQ)
Where is Qlife Holding's headquarters?
Qlife Holding's headquarters is located at Hamntorget 3, Helsingborg.
What is Qlife Holding's latest funding round?
Qlife Holding's latest funding round is IPO.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.